APA

Adams C. M., Anderson K., Artman G., Bizec J., Cepeda R., Elliott J., Fassbender E., Ghosh M., Hanks S., Hardegger L. A., Hosagrahara V. P., Jaffee B., Jendza K., Ji N., Johnson L., Lee W., Liu D., Liu F., Long D., Ma F., Mainolfi N., Meredith E. L., Miranda K., Peng Y., Poor S., Powers J., Qiu Y., Rao C., Shen S., Sivak J. M., Solovay C., Tarsa P., Woolfenden A., Zhang C. & Zhang Y. (20190415). The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. : Journal of medicinal chemistry.

Chicago

Adams Christopher M, Anderson Karen, Artman Gerald, Bizec Jean-Claude, Cepeda Rosemarie, Elliott Jason, Fassbender Elizabeth, Ghosh Malay, Hanks Shawn, Hardegger Leo A, Hosagrahara Vinayak P, Jaffee Bruce, Jendza Keith, Ji Nan, Johnson Leland, Lee Wendy, Liu Donglei, Liu Fang, Long Debby, Ma Fupeng, Mainolfi Nello, Meredith Erik L, Miranda Karl, Peng Yao, Poor Stephen, Powers James, Qiu Yubin, Rao Chang, Shen Siyuan, Sivak Jeremy M, Solovay Catherine, Tarsa Peter, Woolfenden Amber, Zhang Chun and Zhang Yiqin. 20190415. The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. : Journal of medicinal chemistry.

Harvard

Adams C. M., Anderson K., Artman G., Bizec J., Cepeda R., Elliott J., Fassbender E., Ghosh M., Hanks S., Hardegger L. A., Hosagrahara V. P., Jaffee B., Jendza K., Ji N., Johnson L., Lee W., Liu D., Liu F., Long D., Ma F., Mainolfi N., Meredith E. L., Miranda K., Peng Y., Poor S., Powers J., Qiu Y., Rao C., Shen S., Sivak J. M., Solovay C., Tarsa P., Woolfenden A., Zhang C. and Zhang Y. (20190415). The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. : Journal of medicinal chemistry.

MLA

Adams Christopher M, Anderson Karen, Artman Gerald, Bizec Jean-Claude, Cepeda Rosemarie, Elliott Jason, Fassbender Elizabeth, Ghosh Malay, Hanks Shawn, Hardegger Leo A, Hosagrahara Vinayak P, Jaffee Bruce, Jendza Keith, Ji Nan, Johnson Leland, Lee Wendy, Liu Donglei, Liu Fang, Long Debby, Ma Fupeng, Mainolfi Nello, Meredith Erik L, Miranda Karl, Peng Yao, Poor Stephen, Powers James, Qiu Yubin, Rao Chang, Shen Siyuan, Sivak Jeremy M, Solovay Catherine, Tarsa Peter, Woolfenden Amber, Zhang Chun and Zhang Yiqin. The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. : Journal of medicinal chemistry. 20190415.